La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Mesoblast a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Mesoblast..

Mesoblast (NASDAQ:MESO) Azioni, Catena delle Opzioni

Mesoblast

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Limited - American Depositary Shares

Mesoblast Ltd

Meso Numismatics Inc

Canaccord Genuity analyst George Gianarikas maintains Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Buy and lowers the price target from $27 to $25.

News

Price Target

Analyst Ratings

MBLY

Canaccord Genuity Maintains Buy on Mobileye Global, Lowers Price Target to $25

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>).
On Oct. 29, Citigroup analyst Jon Tower maintained Cava Group with a Neutral and raised the price target <a href="https://www.benzinga.com/quote/CAVA/analyst-ratings">from $115 to $140.</a>
When asked about GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), he said, &#8220;You have to have planes last longer. And that means more GE business.&#8221;
On Oct. 22, GE Aerospace reported third-quarter 2024 adjusted revenue growth of 6% year-over-year to $8.943 billion and GAAP revenue of $9.84 billion. The analyst consensus was $9.022 billion.
Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is a &#8220;really good&#8221; company,&#8221; Cramer said. &#8220;It's just one of those companies that you just want to own it — I hate to say this — and forget about it, because that's how good it is.&#8221;
On Oct. 22, Stryker reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $2.77 per share. The company reported quarterly sales of $5.49 billion which beat the analyst consensus estimate of $5.37 billion.
Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) is &#8220;very good,&#8221; he said. &#8220;It's a great place to be, particularly with all the things that are being done with AI.&#8221;
Lantheus Holdings will host a conference call on Wednesday, Nov. 6, to discuss its financial and operating results for the third quarter.
Essential Utilities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) is a &#8220;great&#8221; company, the Mad Money host said. &#8220;That is a terrific stock.&#8221;
Essential Utilities will report earnings for the quarter ending Sept. 30, after the closing bell on Nov. 4.
Price Action:
<ul>
<li>GE Aerospace shares fell 1.6% to settle at $171.78 on Thursday.</li>
<li>Stryker shares dipped 2% to close at $356.28 on Thursday.</li>
<li>Lantheus shares gained 0.4% to settle at $109.84 during the session.</li>
<li>Essential Utilities fell 0.4% to settle at $38.60 on Thursday.</li>
<li>Cava shares fell 0.2% to close at $133.56.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

CAVA

LNTH

WTRG

Jim Cramer Likes Cava Group, Calls This Utilities Stock 'Terrific'

Stifel analyst Matthew Smith maintains Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) with a Buy and raises the price target from $54 to $60.

Stifel Maintains Buy on Altria Group, Raises Price Target to $60

Biotech

General

FEMY

Femasys Inc Announced It Has Been Issued a US Patent For FemBloc A Permanent Birth Control Product With An Anticipated Expiration Date Of 2039

WISeKey PKI and SEALSQ Post-Quantum Technologies Enhance E-Voting Security through Advanced Cybersecurity and AI Integration

LAES

WKEY

WISeKey PKI and SEALSQ Post-Quantum Technologies Unveil New Phase In E-Voting Security With Advanced Cybersecurity And AI Integration

Contracts

Founder Group's Founder Energy Sdn Bhd Subsidiary Receives $3.8M New Solar EPCC Photovoltaic Contract

Macro Economic Events

Econ #s

Economics

Private Nonfarm Payrolls For Oct. Prior Revised From 223K To 192K

Canaccord Genuity analyst Susan Anderson maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $100 to $75.

Canaccord Genuity Maintains Hold on Estee Lauder Cos, Lowers Price Target to $75

SeaStar Medical Reports New Monthly Enrollment Record With 10 Critically Ill Acute Kidney Injury Patients Added To NEUTRALIZE-AKI Pivotal Trial

Private Nonfarm Payrolls For Oct. -28K Vs 90K Expected, 223K Prior

Macro Notification

USA Nonfarm Payrolls For October 12K Vs 106K Est.; 223K Prior

Average Hourly Earnings Month Over Month (Oct) +0.4% vs +0.3% Est.

USA Unemployment Rate For October 4.1% Vs 4.1% Est.; 4.1% Prior

BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) has backtracked on remarks by its Chairman, Ken Mackenzie, about "moving on "from its <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve" rel="noreferrer noopener">failed $49 billion bid</a> for Anglo American (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTCQX">AAUKF</a>).
During BHP's annual shareholder meeting in Brisbane, MacKenzie had suggested that the Anglo American acquisition was a "nice to have, not a must-do" and indicated that BHP had put the deal behind them, <a target="_blank" href="https://www.theguardian.com/business/2024/oct/30/mining-firm-bhp-says-it-has-moved-on-from-failed-anglo-american-bid" rel="noreferrer noopener">reported</a> The Guardian.
"We thought there was an opportunity here to create something unique and special&#8230; But Anglo American shareholders had a different view, and so they moved on. And quite frankly, so have we," he stated.
However, BHP issued a <a target="_blank" href="https://www.bhp.com/news/media-centre/releases/2024/10/statement-regarding-anglo-american-plc" rel="noreferrer noopener">statement</a> clarifying that these comments were not intended to be a formal withdrawal from pursuing the deal under U.K. takeover regulations.
Following a discussion with the U.K. Takeover Panel, BHP confirmed that the panel would not treat MacKenzie's remarks as an official "no offer" statement, meaning the door remains open for a potential future bid.
Initially <a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38423994/worlds-largest-miner-bhp-bids-to-takeover-anglo-american-as-hunt-for-resources-intensify" rel="noreferrer noopener">proposed in April</a>, BHP's bid for Anglo American sought access to Anglo's lucrative copper assets in South America – as the price for the metal crucial in the green energy transition surged toward its <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/05/38901984/silver-rockets-to-11-year-highs-copper-hits-record-peak-gold-approaches-historic-" rel="noreferrer noopener">yearly high in May</a>.
Despite the strategic fit, the deal faced hurdles, particularly concerning Anglo's South African assets. BHP hesitated to retain those due to regulatory complexities and economic risks associated with South Africa's business environment.
Unable to secure the deal, BHP turned to its key assets, looking to expand its Olympic Dam operation in South Australia and the Escondida mine in Chile; however, their domestic operations face challenges that could drive higher costs.
Australia's mining industry has been grappling with high labor expenses as worker shortages and competition drive wages upward. New labor laws, including the "Same Job, Same Pay" initiative, have raised concerns over their potential to <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39647424/bhp-cuts-employee-incentives-misses-performance-goals" rel="noreferrer noopener">increase operational costs</a>.&nbsp;
At the Brisbane meeting, labor issues were a key focus, with hundreds of workers protesting BHP's stance on the new legislation and its effect on profitability.
Still, the company managed to increase its footprint in South America. In July, it <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" rel="noreferrer noopener">announced a bid</a> for Filo Corp (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/FLMMF#OTCQX">FLMMF</a>). Through a 50-50 joint venture with Lundin Mining (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LUNMF#OTC">LUNMF</a>), BHP will spend $2 billion to acquire a 50% stake in the promising Filo del Sol copper project on the Chilean-Argentine border and a 50% stake in Lundin's Josemaria project.
The mandatory standstill on a new bid for Anglo American expires on November 29.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41663633/biggest-gold-etf-posts-highest-monthly-inflows-in-2-5-years-as-investors-rush-to-" target="_blank" rel="noreferrer noopener">Biggest Gold ETF Posts Highest Monthly Inflows In 2.5 Years As Investors Rush To Safe Haven Ahead Of Presidential Election</a></li>
</ul>
Photo via Shutterstock

Large Cap

Commodities

Legal

AAUKF

FLMMF

LUNMF

BHP Backtracks Its Comments On Abandoning Anglo American Deal

Canaccord Genuity analyst Brian McNamara maintains Driven Brands Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRVN#NASDAQ">DRVN</a>) with a Buy and raises the price target from $20 to $21.

DRVN

Canaccord Genuity Maintains Buy on Driven Brands Hldgs, Raises Price Target to $21

JMP Securities analyst John Colantuoni maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Market Outperform and raises the price target from $5000 to $5400.

BKNG

JMP Securities Maintains Market Outperform on Booking Holdings, Raises Price Target to $5400

Earnings

Global Engine Group FY24 EPS $0.021; Revenue $6.33M

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $366 to $384.

ALNY

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384

S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) reported quarterly losses of $(2.95) per share which missed the analyst consensus estimate of $(1.90) by 55.26 percent. This is a 2169.23 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $14.82 million which missed the analyst consensus estimate of $23.00 million by 35.57 percent. This is a 35.72 percent decrease over sales of $23.05 million the same period last year.

Earnings Misses

SANW

S&W Seed Q4 Adj $(2.95) Misses $(1.90) Estimate, Sales $14.82M Miss $23.00M Estimate

Friday,&nbsp;Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported first-quarter 2025 adjusted EPS of $1.88, up 9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.62</a>.
Sales decreased 4% to $52.28 billion, beating the&nbsp;consensus of $50.90 billion. Adjusted operating earnings increased 12% to&nbsp;$625 million.
First-quarter revenue for the Pharmaceutical and Specialty Solutions segment decreased by 5% to&nbsp;$48.0 billion. Excluding the customer contract expiration, revenue increased by 16%, driven by brand and specialty pharmaceutical sales growth <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41679244/cardinal-health-reports-first-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-outlook" rel="noreferrer noopener">from existing customers</a>.
Pharmaceutical and Specialty Solutions segment profit increased 16% to&nbsp;$530 million, driven by a higher contribution from brand and specialty products, including the earlier seasonal launch of COVID-19 vaccine distribution and positive generics program performance.
The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty drugs, and OTC products and offers services for specialty pharmaceuticals, supporting both manufacturers and healthcare providers and pharmacy management services.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40694838/opioid-settlement-drug-distributors-mckesson-cencora-cardinal-health-to-pay-300m-to-health-insurer" rel="noreferrer noopener">Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers</a>
Revenue for the Global Medical Products and Distribution segment increased 3% to&nbsp;$3.1 billion, driven by volume growth from existing customers.
Global Medical Products and Distribution (GMPD) segment profit decreased to&nbsp;$8 million, primarily due to higher manufacturing and health and welfare costs, largely offset by improved net inflationary impacts, including mitigation initiatives and growth from existing customers.
GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, as well as distributes medical, surgical and laboratory products known as national brand products
&#8220;We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,&#8221; said&nbsp;Jason Hollar, CEO of Cardinal Health.
&#8220;The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year,&#8221; Hollar added.
Outlook:&nbsp;Cardinal Health has raised its fiscal year 2025 outlook for adjusted EPS to $7.75-$7.90 from <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b" rel="noreferrer noopener">prior guidance of</a> $7.55-$7.70 versus consensus of $7.63.
The guidance includes an update to the company&#8217;s Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.
The company also updated its Global Medical Products and Distribution segment profit outlook to&nbsp;$140 million&nbsp;to&nbsp;$175 million, from approximately&nbsp;$175 million, primarily due to the impact of higher health and welfare costs.
Additionally, the company updated expectations for its adjusted free cash flow to&nbsp;$1.0 billion&nbsp;to&nbsp;$1.5 billion, from approximately&nbsp;$1.0 billion.
Price Action: CAH stock is trading 2.97% higher at $111.74 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41661764/ford-to-halt-f-150-ev-production-for-7-weeks-next-month" target="_blank" rel="noreferrer noopener">Ford To Halt F-150 EV Production For 7 Weeks Next Month</a></li>
</ul>
Photo via Company

Guidance

Health Care

Movers

Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business

Mesoblast GAAP EPS of -$0.09 beats by $0.63, revenue of $5.9M misses by $1.71M

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Mesoblast (MESO – Research Report), with a price target o...

Mesoblast (MESO) Receives a Buy from Piper Sandler

Bell Potter analyst John Hester maintained a Buy rating on Mesoblast Limited (MEOBF – Research Report) today and set a price target of A$1.40. The ...

Bell Potter Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)

In a report released today, David Stanton from Jefferies upgraded Mesoblast Limited (MEOBF – Research Report) to a Buy, with a price target of A$1....

Mesoblast Limited (MEOBF) was upgraded to a Buy Rating at Jefferies

Mesoblast to issue $50M convertible notes for product launch

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast (MESO) has released an update. Mesoblast Limited, a leader in cellular medicines, has announced a convertible note subscription agreement...

Mesoblast Secures $50M for RYONCIL Launch Prep

Hedge funds pile into healthcare stocks amid dip, Goldman Sachs says

Mesoblast (MESO) has released an update. Mesoblast Limited is making strides in advancing its late-stage pipeline of innovative cellular medicines ...

Mesoblast Advances Cellular Medicines Amid FDA Hopes

Analyst McCarthy holds two days of meetings with Founder & CEO Dr. Itescu and Head of Global Communications Hughes on October 21-22 hosted by Maxim...

Mesoblast management to meet with Maxim

AQST

AXGN

CDNA

CLOV

CRMD

JCRRF

MEOBF

MESO

PSNL

RMTI

Press Releases

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Comments

Mesoblast

Mesoblast (MESO) Opzioni

Mesoblast (NASDAQ:MESO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO